A newly-formed Canadian pharmaceutical company is vying to break into the market with a generic version of one of the most well-known prescription drugs in the world: Ozempic. The company’s endeavour highlights domestic pharmaceutical manufacturing capabilities at a time of geopolitical uncertainties and tariff turmoil. “Having a product that is so broadly recognized — especially by a Canadian company — as our first commercial project is really exciting,” API CEO Andrew MacIsaac said in an interview. The organization brought in specialized equipment from Italy in preparation for generic semaglutide manufacturing, but MacIsaac said it will also be used to produce other medicines. However, Hollis acknowledged that a Canadian-made generic semaglutide may matter little to users.

Source: CBC News March 08, 2026 18:46 UTC